<DOC>
	<DOCNO>NCT01679327</DOCNO>
	<brief_summary>This study evaluate relationship biomarker expression efficacy bevacizumab plus chemotherapy patient unresectable/metastatic colorectal cancer . Before treatment , investigator detect VEGF-A , VEGF-C , VEGF-D , VEGFR-1 , VEGFR-2 , VEGFR-3 expression tumor tissue IHC detect protein expression level plasma ELISA . After least 6 week treatment , investigator detect VEGF-A , VEGF-C , VEGF-D expression level plasma ELISA . The aim study identify whether biomarkers could predict Bevacizumab efficacy .</brief_summary>
	<brief_title>Study Bevacizumab Plus Chemotherapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>More 18years old , male female Pathologically approve unresectable/metastatic colorectal cancer KPS &gt; 70 % ECOG 02 HGB &gt; 80 g/L , NEUT ≥ 1.5x109 /L , PLT ≥ 80x109 /L ; CR &lt; 1.5 x Upper normality， TB &lt; 1.5 X Upper normality，AST ALT &lt; 2.5 x Upper normality . Signed consent Other malignancy simultaneously except situ cervix nonmelanoma skin cancer Pregnancy lactation HGB &lt; 80 g/L , NEUT &lt; 1.5x109 /L , PLT &lt; 80x109 /L ; CR ≥ 1.5 x Upper normality， TB ≥ 2.5 X Upper normality，AST ALT ≥2.5 x Upper normality，AKP ≥ 2.5 X Upper normality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>